Update on gastric cancer treatments and gene therapies

被引：173

作者：

Biagioni, Alessio ^{[1
]}

Skalamera, Ileana ^{[2
]}

Peri, Sara ^{[1
,3
]}

Schiavone, Nicola ^{[1
]}

Cianchi, Fabio ^{[2
]}

Giommoni, Elisa ^{[4
]}

Magnelli, Lucia ^{[1
]}

Papucci, Laura ^{[1
]}

机构：

[1] Univ Florence, Dept Expt & Clin Biomed Sci, Viale GB Morgagni 50, I-50134 Florence, Italy

[2] Univ Florence, Dept Expt & Clin Med, Largo Brambilla 3, I-50134 Florence, Italy

[3] Univ Siena, Dept Biotechnol Chem & Pharm, Via Aldo Moro 2, I-53100 Siena, Italy

[4] AOU Careggi, Dept Oncol & Robot Surg, Med Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy

来源：

CANCER AND METASTASIS REVIEWS | 2019年 / 38卷 / 03期

关键词：

Gastric cancer; Chemotherapy; Metastases; Gene therapy; CRISPR; GROWTH-FACTOR; PHASE-III; PROGNOSTIC-SIGNIFICANCE; GASTROESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; POTENTIAL BIOMARKER; MET INHIBITORS; IN-VIVO; CHEMOTHERAPY;

D O I：

10.1007/s10555-019-09803-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastric cancer is an active topic of clinical and basic research due to high morbidity and mortality. To date, gastrectomy and chemotherapy are the only therapeutic options for gastric cancer patients, but drug resistance, either acquired or primary, is the main cause for treatment failure. Differences in development and response to cancer treatments have been observed among ethnically diverse GC patient populations. In spite of major incidence, GC Asian patients have a significantly better prognosis and response to treatments than Caucasian ones due to genetic discordances between the two populations. Gene therapy could be an alternative strategy to overcome such issues and especially CRISPR/Cas9 represents one of the most intriguing gene-editing system. Thus, in this review article, we want to provide an update on the currently used therapies for the treatment of advanced GC.

引用

页码：537 / 548

页数：12

共 111 条

[1] HER2 testing in gastric cancer: An update [J].

Abrahao-Machado, Lucas Faria ;

Scapulatempo-Neto, Cristovam .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (19) :4619-4625

[2] Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study [J].

Ajani, J. A. ;

Buyse, M. ;

Lichinitser, M. ;

Gorbunova, V. ;

Bodoky, G. ;

Douillard, J. Y. ;

Cascinu, S. ;

Heinemann, V. ;

Zaucha, R. ;

Carrato, A. ;

Ferry, D. ;

Moiseyenko, V. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (17) :3616-3624

[3] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].

Ajani, Jaffer A. ;

Rodriguez, Wuilbert ;

Bodoky, Gyorgy ;

Moiseyenko, Vladimir ;

Lichinitser, Mikhail ;

Gorbunova, Vera ;

Vynnychenko, Ihor ;

Garin, August ;

Lang, Istvan ;

Falcon, Silvia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1547-1553

[4] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[5] Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland [J].

Annunziato, Stefano ;

Kas, Sjors M. ;

Nethe, Micha ;

Yucel, Hatice ;

Del Bravo, Jessica ;

Pritchard, Colin ;

Bin Ali, Rahmen ;

van Gerwen, Bas ;

Siteur, Bjorn ;

Drenth, Anne Paulien ;

Schut, Eva ;

van de Ven, Marieke ;

Boelens, Mirjam C. ;

Klarenbeek, Sjoerd ;

Huijbers, Ivo J. ;

van Miltenburg, Martine H. ;

Jonkers, Jos .

GENES & DEVELOPMENT, 2016, 30 (12) :1470-1480

[6]

[Anonymous], J CLIN ONCOLOGY

[7]

Bang YJ, 2010, LANCET, V376, P1302

[8] Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value [J].

Berlth, Felix ;

Bollschweiler, Elfriede ;

Drebber, Uta ;

Hoelscher, Arnulf H. ;

Moenig, Stefan .

WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (19) :5679-5684

[9] Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer [J].

Bernal, Carolina ;

Aguayo, Francisco ;

Villarroel, Cynthia ;

Vargas, Macarena ;

Diaz, Ignacio ;

Ossandon, Francisco J. ;

Santibanez, Eudocia ;

Palma, Mariana ;

Aravena, Edmundo ;

Barrientos, Carlos ;

Corvalan, Alejandro H. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6264-6269

[10] Type II CRISPR/Cas9 approach in the oncological therapy [J].

Biagioni, A. ;

Chilla, A. ;

Andreucci, E. ;

Laurenzana, A. ;

Margheri, F. ;

Peppicelli, S. ;

Del Rosso, M. ;

Fibbi, G. .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36

← 1 2 3 4 5 6 7 8 9 10 →